In The News

Safety and Efficacy of IDegLira Titrated Once Weekly vs Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

March 3, 2017. This open-label trial evaluated the impact of IDegLira (combined insulin degludec and the glucagon-like peptide-1 inhibitor liraglutide) once or twice weekly in insulin-naïve adults with type 2 diabetes inadequately controlled on metformin ± pioglitazone. A total of 420 patients were randomized to this 32-week non-inferiority trial. IDegLira was titrated either once or twice weekly based on mean pre-breakfast plasma glucose readings. With once-weekly titration, mean A1C decreased from 8.2% to 6.1%; reductions for twice-weekly titration were from 8.1% to 6.0%.

Diabetic Retinopathy: A Position Statement by the American Diabetes Association

March 2017. The American Diabetes Association (ADA) has released a position statement on diabetic retinopathy. This is an update of the ADA’s 2002 position statement.

FDA Approves Combined Dapagliflozin/Saxagliptin for Adults With Type 2 Diabetes

February 28, 2017. The US Food and Drug Administration has approved a once-daily formulation of dapagliflozin 10 mg and saxagliptin 5 mg (trade name Qtern). Qtern provides dual antihyperglycemic therapy to patients with type 2 diabetes by combining a sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor in a single daily tablet. Click here for full article

FDA Approves Label Update for Dulaglutide to Include Use in Combination With Basal Insulin

February 8, 2017. The US Food and Drug Administration has approved a label update for the glucagon-like-1 (GLP-1) receptor agonist dulaglutide. Dulaglutide is now approved for use in combination with basal insulin in adults with type 2 diabetes. This update makes dulaglutide the first GLP-1 receptor agonist indicated for combination use with mealtime insulin or basal insulin.

Chronic Liraglutide Therapy Induces an Enhanced Endogenous Glucagon-like Peptide-1 Secretory Response in Early Type 2 Diabetes

January 2017. This study evaluated the impact of chronic liraglutide therapy on endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Fifty-one patients with type 2 diabetes (mean duration, 2.6 years, +/- 1.9 years) were randomized for 48 weeks to subcutaneous liraglutide or placebo. Patients received an oral glucose tolerance test (OGTT) every 12 weeks, with GLP-1 and GIP area under the curve (AUC) measured at 0, 30, 60, 90, and 120 minutes. No between-group differences were observed for AUC GIP.

Use of Incretin Agents and Risk of Acute and Chronic Pancreatitis: A Population-Based Cohort Study

January 2017. This population-based matched cohort study was conducted in a United Kingdom population to assess pancreatitis risk in patients with type 2 diabetes receiving incretin therapy (either dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists). Adult patients (N=182,428) using ≥1 diabetes medication (excluding insulin) were matched to controls without diabetes.

Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation

January 31, 2017. This prospective, real-world, multicenter study evaluated the impact of insulin vs no insulin therapy on thromboembolic risk in patients with diabetes and atrial fibrillation (AF) being treated with anticoagulation therapy. Rates of stroke and systemic embolism were compared over 1 year based on patient diabetes and insulin use status.

American Association of Clinical Endocrinologists/American College of Endocrinology Make Substantial Updates to Dyslipidemia Clinical Practice Guidelines

January 30, 2017. The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) today announced the online publication of its updated clinical practice guidelines for dyslipidemia management and atherosclerosis prevention. These guidelines introduce a new cardiovascular risk category (“Extreme Risk”), along with far-reaching lipid management goals. Click here for full article

Basal Insulin Degludec (Tresiba) Approved for Teens and Children as Young as 1 Year Old With Diabetes

January 30, 2017. The US Food and Drug Administration has approved an expanded pediatric indication for insulin degludec (Tresiba). With this indication, degludec can now be used to treat patients as young as 1 year old with type 1 or type 2 diabetes. Insulin degludec was approved for adult use in January 2016. Available research indicates that, compared with basal insulin glargine, degludec requires fewer daily injections, allows greater dosing flexibility, and is associated with a flatter blood glucose profile and less hypoglycemia.

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)

February 2017. This cohort analysis evaluated the glucose variability (GV) and the hypoglycemia rates (defined as blood glucose less than 70 mg/dL) associated with 4 common insulin regimens in patients with type 2 diabetes. Patients (N=160) were recruited from endocrinology clinics and were required to be on a stable insulin regimen for a minimum of 6 months with A1C levels ≤7.5%.